Sector Expert: Christopher James

FBR Capital Markets

Image: Christopher James

Christopher James, M.D., is a senior equity research analyst at FBR, focusing on life sciences companies with strong growth potential and developing novel agents for serious diseases including cancer and infectious, neurological, inflammatory, metabolic and cardiovascular diseases. He was previously a senior equity research analyst at Brinson Patrick, Rodman & Renshaw and MLV & Co. Prior to joining Brinson Patrick, Dr. James was chief medical officer and senior vice president of medical affairs at Retrophin, a biotechnology company focused on developing therapeutics for rare and devastating diseases. While at Retrophin, he played a pivotal role in the study design and subsequent acceptance of an investigational new drug application with the cardiorenal division of the FDA to initiate a Phase 2 clinical study in a rare kidney disease called focal segmental glomerulosclerosis. Dr. James has prior buyside experience working at Trivium Capital Management and MSMB Capital Management. Dr. James trained in neurological surgery at Cornell-New York Hospital and Memorial Sloan Kettering Cancer Center. He obtained a medical degree from Yale University School of Medicine and a bachelor of science in biology from Cornell University.



Recent Interviews

Cell Therapy 2015: With Maturity Comes Promise (12/23/14)
stemcellmanipulation580

A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy—a disruptive technology that has, in the past few years, progressed out of preclinical studies and into clinical development. To learn more about the transformative promise of regenerative medicine, and what investors might expect from companies working in the sector in 2015, The Life Sciences Report asked analysts Jason Kolbert of Maxim Group and Dr. Christopher James of Brinson Patrick to discuss the advances that could generate robust returns on investment in coming years.

Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal (12/4/14)
multicoloredbeakers580

Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his clinical experience to the readiness of physicians and patients to adopt new therapies. In this interview with The Life Sciences Report, James gives real-life examples of catalysts and their effects, and highlights three strong biotech plays that could return multiples of invested capital.

Christopher James Turns a Clinical Eye on Biotechs with High Reward Potential (7/31/14)

A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings and take on informed risk hold a short list of companies with huge potential. James, a senior analyst and managing director at Brinson Patrick Securities, is a neurosurgeon by training, and examines new platforms and proposed therapies with a clinician's eye. In this interview with The Life Sciences Report, James turns that eye on three names with dramatic, paradigm-changing technology platforms that could energize portfolios.

Recent Quotes

"We are initiating coverage of BOTA with an Outperform rating."

— Christopher James, FBR & Co. (12/23/15)
more >

"We are initiating coverage of AST with an Outperform rating."

— Christopher James, FBR & Co. (11/18/15)
more >

"There is extraordinary upside potential in STEM."

The Life Sciences Report Interview with Christopher James (12/4/14)
more >

"You have lots of shots on goal with RNN."

The Life Sciences Report Interview with Christopher James (12/4/14)
more >

"RNN ended Q2/14 with $38.3M cash, providing it sufficient runway into H2/16."

— Christopher James, Brinson Patrick Securities Corporation (9/8/14)
more >

"STEM will be first to initiate a controlled Phase 2 study using human neural stem cells."

— Christopher James, Brinson Patrick Securities Corporation (9/8/14)
more >

"RNN has sufficient runway into H2/16: we reiterate our Outperform."

— Christopher James, Brinson Patrick Securities Corporation (8/27/14)
more >

"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging."

The Life Sciences Report Interview with Christopher James (7/31/14)
more >

more comments

"We are very excited about RNN; it's an early-stage oncology company with multiple shots on goal."

The Life Sciences Report Interview with Christopher James (7/31/14)
more >

"We are initiating coverage on STEM with a Market Outperform."

— Christopher James, Brinson Patrick Securities Corporation (7/2/14)
more >

fewer comments


Due to permission requirements, not all quotes are shown.